Monopar to Present at the Jefferies Radiopharma Innovation Summit
March 28 2023 - 07:00AM
GlobeNewswire Inc.
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
biopharmaceutical company focused on developing proprietary
therapeutics designed to extend life or improve the quality of life
for cancer patients, today announced that Chandler Robinson, MD,
Monopar’s Chief Executive Officer, will present at the Jefferies
Radiopharma Innovation Summit next week.
Presentation Details:
Date: April 3, 2023Time: 1:00 – 1:30 pm Location: Jefferies
Conference Center, NYC, New York
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical
company focused on developing proprietary therapeutics designed to
extend life or improve the quality of life for cancer patients.
Monopar's pipeline consists of camsirubicin (Phase 1b) for the
treatment of advanced soft tissue sarcoma; a late-stage preclinical
antibody, MNPR-101, for radiopharmaceutical use in advanced
cancers; and an early-stage camsirubicin analog, MNPR-202, for
various cancers. For more information, visit:
www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc. Investor RelationsKim
R. TsuchimotoChief Financial Officerkimtsu@monopartx.com
Follow Monopar on social media for updates: Twitter:
@MonoparTx LinkedIn: Monopar Therapeutics
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From Sep 2023 to Oct 2023
Monopar Therapeutics (NASDAQ:MNPR)
Historical Stock Chart
From Oct 2022 to Oct 2023